Helix BioPharma Corp. to Present at Rodman & Renshaw Annual Global Investment Conference
AURORA, ON, Sep 5, 2013 (Marketwired via COMTEX) --
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Mr. Robert Verhagen, Chief Executive Officer of the Company, will be presenting at the Rodman & Renshaw Global Investment Conference on September 9, 2013.
The presentation will focus on the activities of Helix in the area of cancer, including an overview of its lead candidates L-DOS47, which is currently in a Phase I/II clinical trial for non-small cell lung cancer, and Topical Interferon Alpha-2b, for the treatment of cervical lesions due to HPV infection. The presentation will be made available through Helix's website soon after the conference.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
FOR FURTHER INFORMATION PLEASE CONTACT:
Helix BioPharma Corp. Tel: 905 841-2300 Email: firstname.lastname@example.org
SOURCE: Helix BioPharma Corp.
[ Back To Technology News's Homepage ]